Grg et al., 2020)
Understanding these pathways can inform provider discussions about titration speed and dose-adjustment expectations
And this is just another classic example of even when we make progress, people with barriers and lower resources just may not be able to experience the benefits of that, said Santa Barbara OBGYN Dr
Dit leidde tot het gebruik van deze medicijnen voor mensen met overgewicht of obesitas, zelfs als ze geen diabetes type 2 hadden
Glucagon-like peptide-1 (GLP-1) agonists, which improve insulin secretion, decrease glucagon secretion, increase satiety (and therefore decrease food intake), and may have beneficial effects on beta-cell function, represent an important addition to treatment options
This can happen for a variety of reasons including neurological conditions, uncontrolled diabetes, viral infections, and as a side effect of medications including GLP-1 agonists